ENLIVEX THERAPEUTICS LTD

Historical 13F Holders

Reported Value, Excluding Options

Total Filings

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for M4130Y106 since 12/18/2024, newest first.

Filer	% of Class	Shares	Form	Filed
Armistice Capital, LLC 13G/A Amendment 4	4.99%	209,340	13G/A Amendment 4	8/14/2025 Event 6/30/2025
Armistice Capital, LLC	4.99%	209,340
Steven Boyd	4.99%	209,340
Armistice Capital, LLC 13G/A Amendment 2	7.5%	1,781,931	13G/A Amendment 2	5/15/2025 Event 3/31/2025
Armistice Capital, LLC	7.5%	1,781,931
Steven Boyd	7.5%	1,781,931
Armistice Capital, LLC 13G/A Amendment 1	9.8%	2,208,000	13G/A Amendment 1	2/14/2025 Event 12/31/2024
Armistice Capital, LLC	9.8%	2,208,000
Steven Boyd	9.8%	2,208,000

Period	Filings	Shares, Excl. Options	Value, Excl. Options	Options Value
2026 Q2	27	4.25 M	$2.34 M	$71.3 k
2026 Q1	36	3.64 M	$3.38 M	$22.4 k
2025 Q4	27	1.32 M	$929 k	$24.8 k
2025 Q3	30	915 k	$950 k	$0
2025 Q2	23	2.56 M	$2.87 M	$88.6 k
2025 Q1	29	3.17 M	$3.08 M	$49.9 k
2024 Q4	27	3.41 M	$3.99 M	$24.5 k
2024 Q3	23	2.57 M	$4.31 M	$40.0 k
2024 Q2	22	2.33 M	$3.31 M	$27.7 k
2024 Q1	23	478 k	$1.81 M	$197 k
2023 Q4	22	233 k	$630 k	$20.5 k
2023 Q3	20	258 k	$408 k	$48.3 k
2023 Q2	23	302 k	$795 k	$199 k
2023 Q1	23	343 k	$1.24 M	$473 k
2022 Q4	27	338 k	$1.32 M	$1.42 M
2022 Q3	24	334 k	$1.41 M	$2.96 M
2022 Q2	26	605 k	$2.89 M	$711 k
2022 Q1	27	846 k	$4.75 M	$311 k
2021 Q4	33	674 k	$4.19 M	$1.29 M
2021 Q3	27	848 k	$8.38 M	$2.61 M
2021 Q2	24	988 k	$8.79 M	$1.40 M
2021 Q1	29	1.08 M	$11.9 M	$3.12 M
2020 Q4	17	430 k	$3.62 M	$1.20 M
2020 Q3	5	321 k	$1.91 M	$0
2020 Q2	9	355 k	$1.80 M	$0
2020 Q1	7	960 k	$4.49 M	$0
2019 Q4	7	80.2 k	$672 k	$0
2019 Q3	6	50.8 k	$1.36 M	$0
2019 Q2	4	21.4 k	$461 k	$0
2019 Q1	3	17.7 k	$219 k	$0